

**A pilot study into the effect of intake of *Fucus vesiculosus*,
an edible brown seaweed, upon menstrual cycle length and hormonal status of
pre-menopausal women**

Christine F. Skibola

School of Public Health, Molecular Epidemiology and Toxicology Laboratory,
University of California, Berkeley, CA 94720

Running Title: Seaweed consumption affects human menstrual cycling and hormone
levels

Address for Correspondence:

Christine F. Skibola, Ph.D.

Division of Environmental Health Sciences

School of Public Health

217 Earl Warren Hall

University of California

Berkeley, California 94720-7360

(510)643-5041 tel/(510)642-0427 fax

email: chrisfs@uclink.berkeley.edu

Abstract

Background: Rates of estrogen-dependent cancers are among the highest in Western countries and lower in the East. These variations may be attributable to differences in dietary exposures such as higher seaweed consumption among Asian populations. The edible brown kelp, *Fucus vesiculosus* (bladderwrack), as well as other brown kelp species, lower plasma cholesterol levels. Since cholesterol is a precursor to sex hormone biosynthesis, kelp consumption may alter circulating sex hormone levels and menstrual cycling patterns. In particular, dietary kelp may be beneficial to women with or at high risk for estrogen-dependent diseases. To test this, bladderwrack was administered to three premenopausal women with abnormal menstrual cycling patterns and/or menstrual-related disease histories.

Case Presentation: Intake of bladderwrack was associated with significant increases in menstrual cycle lengths, ranging from an increase of 5.5 to 14 days. In addition, hormone measurements ascertained for one woman revealed significant anti-estrogenic and pro-progestagenic effects following kelp administration. Mean baseline 17β -estradiol levels were reduced from 626 ± 91 to 164 ± 30 pg/ml ($p=0.04$) following 700 mg/d, which decreased further to 92.5 ± 3.5 pg/ml ($p=0.03$) with the 1.4 g/d dose. Mean baseline progesterone levels rose from 0.58 ± 0.14 to 8.4 ± 2.6 ng/ml with the 700 mg/d dose ($p=0.1$), which increased further to 16.8 ± 0.7 ng/ml with the 1.4 g/d dose ($p=0.002$).

Conclusion: These pilot data suggest that dietary bladderwrack may prolong the length of the menstrual cycle and exert anti-estrogenic effects in pre-menopausal women. Further, these studies also suggest that seaweed may be another important dietary component apart from soy that is responsible for the reduced risk of estrogen-related cancers observed in Japanese populations. However, these studies will need to be performed in well-controlled clinical trials to confirm these preliminary findings.

Background

Epidemiological studies show that incidence rates of estrogen-dependent diseases such as cancers of the breast, endometrium and ovary are among the highest in Western, industrialized countries, while rates are much lower in China and Japan [1, 2]. These disparities may be attributable, in part, to differences in dietary and environmental exposures associated with affluent and modern lifestyles that promote estrogenic stimulation and hormone imbalances [3-5]. Although the mechanisms are not fully understood, epidemiological and experimental data suggest that exposure to estrogens, through endogenous production and exogenous exposures resulting in an imbalance in the estrogen/progesterone ratio, may be the most critical determinants in disease risk [6-8]. In estrogen-sensitive tissues, estrogen triggers cell proliferation, and through prolonged stimulation, hyperplasia [9] and possibly neoplasia can occur. Reproductive factors associated with increased exposure to menstruation resulting in persistent and sustained estrogenic stimulation, such as shorter menstrual cycles, reduced parity, early menarche, and late menopause, are known to increase risk of endometriosis and estrogen-dependent cancers [10, 11], while post-menopausal obesity, hormone replacement therapy and alcohol consumption are associated with increased breast cancer risk [12-14]. Therefore, limiting exposure to estrogens and reducing the overall number of menstrual cycles in one's lifetime through dietary and lifestyle changes may be the simplest means to reduce disease risk. In particular, the identification of dietary compounds that have estrogen-reducing effects holds great promise in developing chemopreventive strategies to abrogate risk of these diseases.

Studies show that Japanese women have longer menstrual cycle lengths (greater than the 28 day average) and lower circulating estrogen levels compared to Western populations [15-17], which until now has been at least partly attributed to the increased intake of soy protein among Asian populations [18-20]. Another less explored component but main staple of the Japanese diet is seaweed, which accounts for approximately 10-25% of their food intake [21, 22]. Other reported estimates daily intakes are as high as 3-13 g/day [23]. A major source of dietary seaweed among Japanese populations is the edible brown kelp, wakame (*Undaria pinnatifida*) and kombu (*Laminaria japonica*). These species and the Atlantic brown kelp, bladderwrack (*Fucus vesiculosus*), have been shown to exert powerful anti-hypertensive activity related to angiotensin-I-converting enzyme inhibition [24], to possess antibacterial and antioxidant properties related to their high polyphenolic content [25], and to prevent dioxin absorption and accelerate dioxin excretion in rats [26]. Other chemopreventive properties such as antiviral activity [27, 28], immunostimulatory effects [29], anti-proliferative effects on 7,12-dimethylbenz(a)-anthracene-induced rat mammary tumors [30, 31], and anti-tumor and anti-metastatic activities in xenograft mouse models [32], have been associated with the high level of sulfated polysaccharides, also known as fucoidans, found in brown seaweed.

Intake of bladderwrack, as well as other brown kelp species, also has been shown to alter cholesterol metabolism and to significantly lower plasma cholesterol levels [33, 34]. A possible mechanism of action involves competitive inhibition by fucosterols found in kelp. Since cholesterol is the precursor involved in steroid hormone biosynthesis, a reduction in cholesterol bioavailability could lower circulating plasma 17 β -estradiol

levels that may lead to alterations in menstrual cycling patterns in pre-menopausal women. Until now, no studies have been performed in humans to determine the effects of brown kelp on menstrual cycling patterns and sex hormone status in pre-menopausal women, particularly in women with or at risk for estrogen-dependent diseases. To explore the hypothesis that kelp consumption could reduce circulating 17β -estradiol levels and attenuate menstrual cycle irregularities, bladderwrack was administered to three pre-menopausal women with abnormal menstrual cycling patterns and/or menstrual-related disease histories.

Case presentation

Three pre-menopausal women with abnormal menstrual cycling histories volunteered for the present study. An abnormal menstrual cycle was defined as one or more of the following: menstrual cycles of <26 or >32 days in length; menstrual cycles consisting of >8 menstruating days; or anovulatory menstrual cycling. Study subject characteristics are outlined in Table 1. Subject 1 had a history of hypermenorrhea (excessive blood loss during menstruation), polymenorrhea (shorter than average menstrual cycle length of 28 days), anovulatory menstrual cycles, and was diagnosed with luteal phase deficiency and endometriosis (through laparoscopy). Subject 2 suffered from hypermenorrhea and polymenorrhea. Subject 3 suffered from hypermenorrhea and was diagnosed with endometriosis. All three women reported a history of dysmenorrhea (painful menses). Otherwise, all women were in general good health and free of any chronic diseases. All women were active and exercised approximately three times per week. No hormones or

other medications were taken for >3 months prior to the inception of the study. No soy protein products were consumed during the study period.

The protocol was approved by the Committee for the Protection of Human Subjects of the University of California at Berkeley. The nature of the study was explained, and written informed consent was obtained from all study subjects.

Source and dose of bladderwrack (*Fucus vesiculosus*)

Dried, powdered bladderwrack (*Fucus vesiculosus*) was obtained from Maine Coast Sea Vegetables (Franklin, ME) and encapsulated in 350 mg capsules. Two capsules were administered daily for the low dose treatment (700 mg) and four capsules were administered daily for the high dose treatment (1.4 g). Bladderwrack dosage levels were chosen to fall within the range of reported dietary seaweed intakes (10-25%) of the total diet reported for Japanese populations [21, 22]. This was calculated by assuming a total 500 g/d total dietary intake and a range between 50-125 g/d (wet weight) or 0.5-1.25 g/d (dry weight) seaweed intake. This calculation falls below the estimated 3-13 g/d intake reported by Teas et al. [23].

Experimental protocols

Details of the study protocol are outlined in Table 2. All women provided self-reported menstrual cycling histories for the three months prior to the treatment period. In addition, 17 β -estradiol and progesterone serum measurements were taken for Subject 1 throughout the course of the study as outlined in Table 2. Ovulation was monitored through body

basal temperature. Since the average length of her cycle was 16 days prior to treatment and she was not ovulating at the inception of the study, baseline hormone levels were ascertained on a set day (menstrual cycle day 12) for two consecutive cycles prior to the administration of 700 mg/d bladderwrack for two additional cycles. During the treatment period, serum hormone levels were measured on days 12 and 21 for the first cycle (which was another anovulatory cycle) and on day 21 thereafter during the treatment period. Subjects 2 and 3 were administered 700 mg/d of bladderwrack beginning on day 21 of their menstrual cycles and followed for two consecutive cycles. Subsequently, Subjects 1 and 3 agreed to continue the experiment for two additional cycles at which time they received a daily dose of 1.4 g/d kelp. Menstrual cycling logs were maintained on all subjects during the entire course of the experiment. Subjects were monitored at least weekly to insure compliance to the supplement regimen.

Hormone assays

All hormone assays were performed by Quest Laboratories (San Diego, CA), an outside-certified clinical laboratory. Serum 17β -estradiol and progesterone levels were measured in duplicate by radioimmunoassays. Blank and control sera were run with each assay. The coefficient of variation (a measure of laboratory error) was consistently low (<15%) for 17β -estradiol and progesterone.

Statistical methods

Statistical analyses were performed by unpaired t-tests (2-sided) with a commercially available statistical software package (Stata, College Station, Texas). All statistical tests

were considered significant for $p \leq 0.05$. Results are referred to as borderline significant for $0.05 < p \leq 0.10$.

Clinical findings

There were no adverse side effects reported and bladderwrack was well tolerated by all three women.

Effects of treatment on length of menstrual cycle and total days of menstruation

Following treatment, all women exhibited a significant increase in menstrual cycle lengths (Figure 1). Specifically, in Subject 1, who had a 30-year history of irregular menses, the menstrual cycle length increased from an average of 16.3 ± 0.6 days to 26.0 ± 1.4 days with the low dose treatment ($p < 0.002$), which increased by approximately 5 additional days to 31.2 ± 1.1 days following administration of the higher dose ($p < 0.001$). In Subject 2, the average cycle length increased 5.5 days, from 23.0 ± 1.7 to 28.5 ± 0.7 days ($p = 0.03$). Subject 3 exhibited a 4-day increase in menstrual cycle length from 27.3 ± 0.6 to 31.5 ± 0.7 days with the 700 mg dose ($p = 0.005$) that increased by approximately 6 more days to 36.0 ± 2.8 days with the 1.4g dose ($p = 0.01$).

Along with increased menstrual cycle lengths, all women reported marked reductions in blood flow and average number of days of menstruation following bladderwrack treatment (Figure 2). Subject 1 reported the most significant reduction in total days of menstruation, changing from an average 9.3 ± 0.6 to 6.3 ± 1.8 days ($p = 0.06$) with the low dose and to 4.5 ± 0.7 average days with the high dose ($p < 0.003$). Subject 2, who only took

the low dose, also experienced a marked reduction in number of days of menstruation, from 8.0 ± 1.0 to 5.3 ± 2.5 days ($p=0.06$). Subject 3 exhibited a decrease in total menstruating days averaging from 6.3 ± 1.5 to 5.8 ± 0.4 days ($p=0.65$) with the low dose, and to 3.5 ± 0.7 days ($p=0.10$) with the 1.4 g/d dose. Subjects 1 and 3, who both suffered from endometriosis, reported substantial alleviation from pain during menstruation and throughout the menstrual cycle following bladderwrack treatment.

Subject 1 also reported an ovulatory cycle following 2 months on the 700 mg/d kelp intervention, and continued to have ovulatory cycles while on the 1.4 g/d dose.

Effects of treatment on serum estradiol and progesterone levels

A significant anti-estrogenic and pro-progestagenic dose response was observed in plasma estradiol and progesterone levels in Subject 1 (Table 3). Specifically, the mean baseline 17β -estradiol levels were reduced from 626 ± 91 to 164 ± 30 pg/ml ($p=0.04$) with the low dose (700 mg/d), which decreased further to 92.5 ± 3.5 pg/ml ($p=0.03$) with the higher dose (1.4 g/d). Furthermore, mean baseline progesterone level rose from 0.58 ± 0.14 to 8.4 ± 2.6 ng/ml with the lower 700 mg/d dose ($p=0.1$), which increased further to 16.8 ± 0.7 ng/ml with the 1.4 g/d dose ($p=0.002$).

Discussion of clinical findings

The results of this preliminary pilot study suggest that bladderwrack consumption can effectively increase the length of the menstrual cycle and reduce the total number of days of menstruation in pre-menopausal women. These effects were most marked in the two

women that had shorter than average cycles (16 and 23 days) versus the normal range of 26 to 32 days seen in women in Western populations. Menstrual cycles were further lengthened with increasing dose, which may suggest a linear dose-response effect. However, since there was not a sufficient washout period between the 700 and 1400 mg/d doses, an effect of length of time of dosing rather than a dose response effect cannot be ruled out. Nonetheless, these marked increases in menstrual cycle length may have beneficial health effects in lowering risk of estrogen-dependent diseases such as endometriosis and ovarian, endometrial, and breast cancers as reported in a number of studies [16, 35-38]. Menstrual characteristics are surrogate markers that may reflect a woman's overall exposure to and production of endogenous hormones. Shorter menstrual cycle lengths and prolonged menstruation confer longer follicular and luteal phases where estrogen and progesterone levels and endometrial and breast cell proliferation rates are at their highest. A nearly fourfold increase in mitotic activity in the breast lobules occurs during the luteal phase of the menstrual cycle [39], while the highest proliferation rates (nearly 100-fold) in the endometrium occur during the follicular phase [40]. Therefore, fewer menstrual cycles over a woman's lifetime would decrease the amount of time during which the breast and endometrial epithelia would be exposed to high levels of proliferation, which may decrease overall disease risk.

Bladderwrack consumption also led to a marked reduction in circulating 17β -estradiol levels and an increase in progesterone levels in a subject who exhibited high serum estrogen levels and progesterone deficiency prior to the intervention. While estrogen's proliferative effects on mammary gland development and endometrial and breast

tumorigenesis are well documented, progesterone's role in these processes is not as well defined. Studies show that progesterone deficiency is associated with increased endometrial cancer incidence [41], and that progesterone inhibits estrogen-induced luminal epithelial proliferation in the uterus [42]. However, progesterone has been shown to both stimulate and inhibit the growth of experimental mammary tumors [43], and the use of synthetic progestins in hormone replacement therapy has been associated with an increased risk of breast cancer [43]. Experimental rat models have elucidated progesterone's vital role in pregnancy-induced morphological changes in the breast, which confer protection against breast cancer [44]. Further, epidemiological studies suggest that it is not pregnancy alone but early first parity and increasing number of pregnancies that are associated with reduced breast cancer risk [45, 46]. These studies suggest that the effects of progesterone in breast cancer risk may be dependent on timing and the type and level of progesterone/progestin exposure. Thus, the anti-estrogenic/pro-progestagenic activity of kelp observed in this study warrants further investigation in its role in breast cancer and other hormone-dependent diseases.

Study limitations

Due to the small number of subjects and the lack of a control group, this study will need to be repeated in a larger, randomized population of women with placebo controls. Other weaknesses of the present study are the lack of data on luteinizing hormone and follicular stimulating hormone levels which would provide pertinent information regarding the effects of dietary bladderwrack on ovulation and the luteal and follicular phases of the menstrual cycle. The potential beneficial impact that dietary bladderwrack may have on

abrogating symptoms of endometriosis warrants a closer look at a larger population of women suffering from this disease. However, studies should also be performed in women with normal menstrual cycles who have sex hormone levels within clinically normal ranges to determine the impact of dietary kelp on menstrual cycling patterns and hormone levels in the general population.

Conclusions

The observed responses to bladderwrack consumption in this study suggest that dietary modification may lead to significant changes in the regulation of the menstrual cycle by increasing the length of the cycle, stimulating ovulation, and lowering the estrogen/progesterone ratio in premenopausal women. Such changes may be beneficial particularly with regard to women at high risk of estrogen-dependent diseases or who are experiencing fertility problems. Results from these preliminary experiments also suggest that bladderwrack administration may alleviate hypermenorrhea and dysmenorrhea, which may provide some relief in the treatment of endometriosis. Although these reported effects are generally in a beneficial direction, their clinical significance is yet to be determined in a well-controlled study.

Future Directions

The critical role of hormones in breast, endometrial, and ovarian cancers in women and prostate cancer in men has long been recognized. Given the vast rise of these cancers in the U.S. and our limited success with prevention and treatment, there is clearly a need for the identification of novel, non-cytotoxic chemopreventive agents. Future investigations

should clarify the role of bladderwrack and other seaweed species on estrogen and progesterone metabolism, to evaluate its potential binding affinity to estrogen and progesterone receptors, and to determine its effects on proliferation in hormone-sensitive tissues. These investigations should also be expanded to include effects of bladderwrack on other sex hormones including the androgens and gonadotropins. In this regard, animal and *in vitro* studies are currently underway in our laboratory to elucidate the potential mechanisms and clinical relevance of bladderwrack bioactivity, and to identify and isolate the active components involved.

Competing Interests

No interests declared.

Acknowledgements

Written consent was obtained from the patients for publication of study. This work was supported by the National Foundation for Cancer Research and NIH grant P30 ES01896.

Thanks to Dr. Martyn T. Smith for his guidance and support.

References

1. Parkin DM, Pisani P, Ferlay J: **Estimates of the worldwide incidence of 25 major cancers in 1990.** *Int J Cancer* 1999, **80**:827-841.
2. Parkin DM, Pisani P, Ferlay J: **Global cancer statistics.** *CA Cancer J Clin* 1999, **49**:33-64, 31.
3. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN: **Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States).** *Cancer Causes Control* 1998, **9**:199-207.
4. McTiernan A: **Behavioral risk factors in breast cancer: can risk be modified?** *Oncologist* 2003, **8**:326-334.
5. Tavani A, Bosetti C, Dal Maso L, Giordano L, Franceschi S, La Vecchia C: **Influence of selected hormonal and lifestyle factors on familial propensity to ovarian cancer.** *Gynecol Oncol* 2004, **92**:922-926.
6. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR: **Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group.** *Ann Intern Med* 1999, **130**:270-277.
7. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE: **Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.** *J Natl Cancer Inst* 1998, **90**:1292-1299.
8. Baskin GB, Smith SM, Marx PA: **Endometrial hyperplasia, polyps, and adenomyosis associated with unopposed estrogen in rhesus monkeys (*Macaca mulatta*).** *Vet Pathol* 2002, **39**:572-575.
9. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL: **Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.** *J Steroid Biochem Mol Biol* 2003, **86**:477-486.
10. Hinkula M, Pukkala E, Kyyronen P, Kauppila A: **Grand multiparity and incidence of endometrial cancer: a population-based study in Finland.** *Int J Cancer* 2002, **98**:912-915.
11. Daniels M, Merrill RM, Lyon JL, Stanford JB, White GL: **Associations between breast cancer risk factors and religious practices in Utah.** *Prev Med* 2004, **38**:28-38.
12. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE, Jr., Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR: **Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.** *J Natl Cancer Inst* 2003, **95**:1218-1226.

13. Beral V: **Breast cancer and hormone-replacement therapy in the Million Women Study.** *Lancet* 2003, **362**:419-427.
14. Tjonneland A, Thomsen BL, Stripp C, Christensen J, Overvad K, Mellemkaer L, Gronbaek M, Olsen JH: **Alcohol intake, drinking patterns and risk of postmenopausal breast cancer in Denmark: a prospective cohort study.** *Cancer Causes Control* 2003, **14**:277-284.
15. Shimizu H, Ross RK, Bernstein L, Pike MC, Henderson BE: **Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan.** *Br J Cancer* 1990, **62**:451-453.
16. Olsson H, Landin-Olsson M, Gullberg B: **Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease.** *J Natl Cancer Inst* 1983, **70**:17-20.
17. Key TJ, Chen J, Wang DY, Pike MC, Boreham J: **Sex hormones in women in rural China and in Britain.** *Br J Cancer* 1990, **62**:631-636.
18. Lu LJ, Anderson KE, Grady JJ, Kohen F, Nagamani M: **Decreased ovarian hormones during a soya diet: implications for breast cancer prevention.** *Cancer Res* 2000, **60**:4112-4121.
19. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M: **Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease.** *Am J Clin Nutr* 1984, **40**:569-578.
20. Cassidy A, Bingham S, Setchell KD: **Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women.** *Am J Clin Nutr* 1994, **60**:333-340.
21. Kagawa Y: **Impact of Westernization on the nutrition of Japanese: changes in physique, cancer, longevity and centenarians.** *Prev Med* 1978, **7**:205-217.
22. Wood CG: **Seaweed extracts: a unique ocean resource.** *J Chem Educ* 1974, **51**:449-452.
23. Teas J, Hebert JR, Fitton JH, Zimba PV: **Algae - a poor man's HAART?** *Med Hypotheses* 2004, **62**:507-510.
24. Sato M, Oba T, Yamaguchi T, Nakano T, Kahara T, Funayama K, Kobayashi A: **Antihypertensive effects of hydrolysates of wakame (*Undaria pinnatifida*) and their angiotensin-I-converting enzyme inhibitory activity.** *Ann Nutr Metab* 2002, **46**:259-267.
25. Abdussalam S: **Drugs from seaweeds.** *Med Hypotheses* 1990, **32**:33-35.
26. Morita K, Nakano T: **Seaweed accelerates the excretion of dioxin stored in rats.** *J Agric Food Chem* 2002, **50**:910-917.
27. Luscher-Mattli M: **Polyanions--a lost chance in the fight against HIV and other virus diseases?** *Antivir Chem Chemother* 2000, **11**:249-259.
28. Schaeffer DJ, Krylov VS: **Anti-HIV activity of extracts and compounds from algae and cyanobacteria.** *Ecotoxicol Environ Saf* 2000, **45**:208-227.
29. Cooper R, Dragar C, Elliot K, Fitton J, Godwin J, Thompson K: **GFS, a preparation of Tasmanian *Undaria pinnatifida* is associated with healing and inhibition of reactivation of Herpes.** *BMC Complement Altern Med* 2002, **2**:11.
30. Funahashi H, Imai T, Tanaka Y, Tsukamura K, Hayakawa Y, Kikumori T, Mase T, Itoh T, Nishikawa M, Hayashi H, Shibata A, Hibi Y, Takahashi M, Narita T:

- Wakame seaweed suppresses the proliferation of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors in rats.** *Jpn J Cancer Res* 1999, **90**:922-927.
31. Teas J, Harbison ML, Gelman RS: **Dietary seaweed (Laminaria) and mammary carcinogenesis in rats.** *Cancer Res* 1984, **44**:2758-2761.
 32. Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H: **Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities.** *Biochem Pharmacol* 2003, **65**:173-179.
 33. Ara J, Sultana V, Qasim R, Ahmad VU: **Hypolipidaemic activity of seaweed from Karachi coast.** *Phytother Res* 2002, **16**:479-483.
 34. Kaneda T, Tokuda S, Arai K: **Studies on the effects of marine products on cholesterol metabolism, 1. The effects of edible seaweed.** *Bulletin Jap Soc Sci Fish* 1963, **29**:1020-1035.
 35. Xu WH, Xiang YB, Ruan ZX, Zheng W, Cheng JR, Dai Q, Gao YT, Shu XO: **Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai.** *Int J Cancer* 2004, **108**:613-619.
 36. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC: **Ovulation and risk of epithelial ovarian cancer.** *Int J Cancer* 2003, **104**:228-232.
 37. Frackiewicz EJ: **Endometriosis: an overview of the disease and its treatment.** *J Am Pharm Assoc (Wash)* 2000, **40**:645-657; quiz 699-702.
 38. Beiler JS, Zhu K, Hunter S, Payne-Wilks K, Roland CL, Chinchilli VM: **A case-control study of menstrual factors in relation to breast cancer risk in African-American women.** *J Natl Med Assoc* 2003, **95**:930-938.
 39. Ramakrishnan R, Khan SA, Badve S: **Morphological changes in breast tissue with menstrual cycle.** *Mod Pathol* 2002, **15**:1348-1356.
 40. Felix JC, Farahmand S: **Endometrial glandular proliferation and estrogen receptor content during the normal menstrual cycle.** *Contraception* 1997, **55**:19-22.
 41. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B: **Cancer incidence in a cohort of infertile women.** *Am J Epidemiol* 1998, **147**:1038-1042.
 42. Lai MD, Jiang MJ, Wing LY: **Estrogen stimulates expression of p21Waf1/Cip1 in mouse uterine luminal epithelium.** *Endocrine* 2002, **17**:233-239.
 43. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: **Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.** *Jama* 2003, **289**:3254-3263.
 44. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: **Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy.** *Proc Natl Acad Sci U S A* 1999, **96**:2520-2525.
 45. Lee SH, Akuete K, Fulton J, Chelmow D, Chung MA, Cady B: **An increased risk of breast cancer after delayed first parity.** *Am J Surg* 2003, **186**:409-412.
 46. Oran B, Celik I, Erman M, Baltali E, Zengin N, Demirkazik F, Tezcan S: **Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study.** *Med Oncol* 2004, **21**:31-40.




Figure 1. Average menstrual cycle length in days for Subjects 1-3 at baseline (black bars) and following bladderwrack administration of 700 mg/d (diagonal striped bars) and 1.4 g/d (white bars).

Black bars indicate the averages of 3 menstrual cycles. Diagonal striped and white bars indicate the averages of 2 menstrual cycles.

Whiskers indicate standard deviations.

*P value <0.05.




Figure 2. Average number of days of menstruation per cycle for Subjects 1-3 at baseline (black bars) and following bladderwrack administration of 700 mg/d (diagonal striped bars) and 1.4 g/d (white bars).

Black bars indicate averages of 3 menstrual cycles. Diagonal striped and white bars indicate the averages of 2 menstrual cycles.

Whiskers indicate standard deviations.

*P value<0.05.

Table 1. Study Subject Characteristics

Subject	Age	Body Weight (lb)	Menstrual Cycle History	Medical Conditions/Health Status	Medications
1	43	142	hypermenorrhea, polymenorrhea,dysmenorrhea, luteal phase deficiency	endometriosis; otherwise healthy	none
2	42	138	hypermenorrhea, polymenorrhea, dysmenorrhea	general good health	none
3	21	126	hypermenorrhea, dysmenorrhea	endometriosis; otherwise healthy	none

Table 2. Treatment protocol and timeline

Subject	Pretreatment menstrual cycling history obtained	Pretreatment serum 17β-estradiol and progesterone levels ascertained (Cycle and day)	Treatment period/dose	Treatment serum 17β-estradiol and progesterone levels ascertained (Cycle and day)	Treatment period/dose	Treatment serum 17β-estradiol and progesterone levels ascertained (Cycle and day)
1	Cycles 1-3	Cycle 2, day 12 Cycle 3, day 12	Cycle 4-5/ 700 mg/d	Cycle 4, day 12 Cycle 4, day 21 Cycle 5, day 21	Cycle 6-7/ 1.4 g/d	Cycle 6, day 21 Cycle 7, day 21
2	Cycles 1-3	NA	Cycle 4-5/ 700 mg/d	NA	NA	NA
3	Cycles 1-3	NA	Cycle 4-5/ 700 mg/d	NA	Cycle 6-7/ 1.4 g/d	NA

Table 3. Average circulating plasma 17 β -estradiol and progesterone levels prior to and during bladderwrack intervention for Subject 1.

	Pre-treatment baseline levels	700 mg/d dose	P-value	1.4 g/d dose	P-value
17 β -estradiol (pg/ml)	626 \pm 91	164 \pm 30	0.04	92.5 \pm 3.5	0.03
Progesterone (ng/ml)	0.58 \pm 0.14	8.4 \pm 2.6	0.10	16.8 \pm 0.7	0.002

All measures are from 2 month averages \pm standard deviation.